Rivaroxaban is an adequate treatment for thromboprophylaxis after total knee arthroplasty
3148 patients who underwent total knee arthroplasty were randomized to thromboprophylaxis using either orally administer rivaroxaban or subcutaneous injection of enoxaparin. This study assessed the efficacy of thromboprophylaxis treatment with rivaroxaban and assessed it's non-inferiority to enoxaparin. The results of this study indicate that rivaroxaban is superior in comparison to enoxaparin for the use in patients undergoing total knee arthroplasty.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου